"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 5 | 3 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 1 | 4 |
| 2012 | 5 | 7 | 12 |
| 2013 | 4 | 3 | 7 |
| 2014 | 6 | 3 | 9 |
| 2015 | 9 | 8 | 17 |
| 2016 | 8 | 7 | 15 |
| 2017 | 9 | 8 | 17 |
| 2018 | 16 | 6 | 22 |
| 2019 | 6 | 6 | 12 |
| 2020 | 8 | 10 | 18 |
| 2021 | 8 | 7 | 15 |
| 2022 | 0 | 16 | 16 |
| 2023 | 0 | 12 | 12 |
| 2024 | 5 | 13 | 18 |
| 2025 | 10 | 9 | 19 |
| 2026 | 3 | 6 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood. 2026 May 07; 147(19):2215-2225.
-
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types. JCO Precis Oncol. 2026 May; 10(5):e2501150.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14; 10(7):2441-2451.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338.
-
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. Blood. 2026 Jan 01; 147(1):24-34.
-
Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers. Aging Cell. 2026 Jan; 25(1):e70358.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 09; 9(23):5954-5964.